Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction

Journal of the American College of Cardiology

Volumn 37, Issue 7, 2001, Pages 1781-1787

  Richards, A Mark ^a   Doughty, Robert ^b   Nicholls, M Gary ^d   MacMahon, Stephen ^c   Sharpe, Norman ^b   Murphy, Judy ^b   Espiner, Eric A ^a   Frampton, Christopher ^a   Yandle, Timothy G ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Institute for Health Research   (Australia)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NEUROHORMONE; PLACEBO; VERAPAMIL;

AMINO TERMINAL SEQUENCE; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ADRENOMEDULLIN; BIOLOGICAL MARKERS; CARBAZOLES; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; PROGNOSIS; PROPANOLAMINES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0035369468     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01269-4     Document Type: Article

References (33)

1. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
2. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies Of Left Ventricular Dysfunction (SOLVD)
3. Activation of neurohumoral systems in postinfarction left ventricular dysfunction
4. Plasma norepinephrine, plasma renin activity and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II
5. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction
6. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
7. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
8. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
9. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
10. The amino-terminal portion of pro-brain natriuretic peptide (pro-BNP) circulates in human plasma
11. Immunoractive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment
12. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
13. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma
14. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma
15. Adrenomedullin in experimental congestive heart failure: Cardiorenal activation
16. Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure
17. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure
18. Plasma adrenomedullin concentration in patients with heart failure
19. Cardiac secretion of adrenomedullin in human heart failure
20. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction
21. Effects of carvedilol, a vasodilator beta-blocker, in patients with congestive heart failure due to ischemic heart disease
22. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
23. The measurement of adrenomedullin (1-52) in human plasma by radioimmunoassay: Plasma levels, adsorption and storage
24. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction
25. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
26. The Cardiac Insufficiency BIsoprolol Study II (CIBIS-II): A randomised trial
27. Effect of metoprolol CR/XL in chronic heart failure: MEtoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF)
28. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: A new antihypertensive mechanism
29. Induction of a myocardial adrenomedullin signaling system during ischemic heart failure in rats
30. Enhanced adrenomedullin production by mechanical stretching in cultured rat cardiomyocytes
31. Effects of vasoactive substances and cAMP-related compounds on adrenomedullin production in cultured vascular smooth muscle cells
32. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
33. Prognostic value of neurohumoral activation in patients with an acute myocardal infarction: Effect of captopril